二、管理层的责任 华康医疗公司管理层的责任是提供真实、合法、完整的相关资料，按照中国证 券监督管理委员会《监管规则适用指引——发行类第7号》的规定编制《关于前次 募集资金使用情况的报告》，并保证其编制的《关于前次募集资金使用情况的报告》 内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 三、注册会计师的责任 我们的责任是在实施鉴证工作的基础上对华康医疗公司管理层编制的《关于前 次募集资金使用情况的报告》提出鉴证结论。 前次募集资金使用情况鉴证报告 中汇会鉴[2024]5797号 武汉华康世纪医疗股份有限公司全体股东： 我们鉴证了后附的武汉华康世纪医疗股份有限公司(以下简称华康医疗公司) 管理层编制的截至2023年12月31日的《关于前次募集资金使用情况的报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供华康医疗公司向中国证券监督管理委员会申请发行可转换公 司债券时使用，不得用作任何其他目的。我们同意本鉴证报告作为华康医疗公司发 行可转换公司债券的必备文件，随其他申报材料一起上报。 四、工作概述 (本页无正文，为武汉华康世纪医疗股份有限公司《前次募集资金使用情况鉴 证报告》之签字盖章页) 中 ...

证券代码：301235 证券简称：华康医疗 公告编号：2024-035 武汉华康世纪医疗股份有限公司 第二届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会召开情况 武汉华康世纪医疗股份有限公司（以下简称"公司"）第二届监事会第十三次会 议于 2024 年 4 月 28 日（星期日）在公司会议室以现场结合通讯方式召开。会议通知 已于 2024 年 4 月 22 日以邮件、通讯方式通知到各位监事。本次会议由监事会主席彭 胡杨先生主持，应到监事 3 人，实到监事 3 人。 本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《武汉华康世纪医疗股份有 限公司章程》（以下简称"《公司章程》"）以及有关法律、法规的规定。 二、监事会会议审议情况 会议以记名投票表决的方式，一致通过了以下议案： （二）审议通过《关于<公司前次募集资金使用情况的报告>的议案》 根据《公司法》《证券法》《上市公司证券发行注册管理办法》《深圳证券交易 所上市公司自律监管指引第2号——创业板上 ...

证券代码： 301235 证券简称：华康医疗 公告编号：2024-036 武汉华康世纪医疗股份有限公司（以下简称"公司"）于 2023 年 4 月 21 日召开第二届董事会第五次会议和 2023 年 5 月 16 日召开的 2022 年年度股东大 会审议通过了公司向不特定对象发行可转换公司债券相关事宜。根据上述会议决 议，公司本次向不特定对象发行可转换公司债券方案的决议有效期及授权董事会 及其授权人士全权办理与本次发行相关事宜的有效期为自 2022 年度股东大会临 时股东大会审议通过之日起十二个月内有效。 中国证券监督管理委员会于 2024 年 2 月 1 日出具《关于同意武汉华康世纪 医疗股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监许可 [2024]220 号），同意公司本次向不特定对象发行可转换公司债券注册，该批复 自同意注册之日起 12 个月内有效。 武汉华康世纪医疗股份有限公司 关于向不特定对象发行可转换公司债券决议及授权 延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 鉴于公司本次向不特定对象发行可转换公司债券方案的决议及 ...

证券代码：301235 证券简称：华康医疗 公告编号：2024-034 武汉华康世纪医疗股份有限公司 第二届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉华康世纪医疗股份有限公司（以下简称"公司"）第二届董事会第十四 次会议于 2024 年 4 月 28 日（星期日）在公司会议室召开。会议通知已于 2024 年 4 月 22 日以电话及邮件方式向公司全体董事发出。本次会议应到董事 7 人， 实到董事 7 人。会议由董事长谭平涛先生主持。 本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《武汉华康世纪医疗股 份有限公司章程》（以下简称"《公司章程》"）以及有关法律、法规的规定。 二、董事会会议审议情况 经出席会议的全体董事认真审议，通过了以下议案： （一）审议通过《关于向不特定对象发行可转换公司债券决议及授权延期 的议案》 具体内容详见同日刊登于巨潮资讯网（http://www.cninfo.com.cn）上的《关 于向不特定对象发行 ...

武汉华康世纪医疗股份有限公司 关于前次募集资金使用情况的报告 根据中国证券监督管理委员会印发的《监管规则适用指引——发行类第 7 号》 的规定，武汉华康世纪医疗股份有限公司(以下简称"公司"或者"本公司")编制 了截至 2023 年 12 月 31 日(以下简称截止日)的前次募集资金使用情况报告如下： 一、前次募集资金基本情况 (一) 前次募集资金到位情况 本公司经中国证券监督管理委员会《关于同意武汉华康世纪医疗股份有限公司 首次公开发行股票注册的批复》(证监许可[2021]4121号)同意注册，由主承销商华 英证券有限责任公司通过深圳证券交易所系统采用向战略投资者定向配售、网下向 符合条件的投资者询价配售、网上向持有深圳市场非限售Ａ股股份和非限售存托凭 证市值的社会公众投资者定价发行相结合的方式，向社会公开发行了人民币普通股 (A股)股票2,640.00万股，发行价为每股人民币为39.30元，共计募集资金总额为人 民币103,752.00万元，扣除发行费用8,801.72万元，实际募集资金净额为人民币 94,950.28万元。上述募集资金已于2022年1月25日到账，上述募集资金到位情况业 经中汇会计师事务 ...

根据证监会《上市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等要求，武汉华康世纪医疗股份有限公司（以下简称"公司"）董事会， 就公司在任独立董事余亮、齐亮、郭孟焕的独立性情况进行评估并出具如下专项 意见： 经核查独立董事余亮、齐亮、郭孟焕的任职经历以及签署的相关自查文件， 上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》中对 独立董事独立性的相关要求。 武汉华康世纪股份有限公司 董事会 武汉华康世纪股份有限公司 董事会对独立董事独立性评估的专项意见 2024 年 4 月 27 日 ...

武汉华康世纪医疗股份有限公司 独立董事述职报告 武汉华康世纪医疗股份有限公司 2023年度独立董事述职报告 本人未在公司担任除独立董事、董事会专门委员会委员以外的任何职务，也 未在公司主要股东单位担任任何职务，与公司以及主要股东之间不存在妨碍本人 进行独立客观判断的关系，不存在影响独立董事独立性的情况。 二、独立董事2023年度履职情况 （一）出席董事会及股东大会情况 2023年度公司共召开了8次董事会会议，5次股东大会会议。本人出席董事会 会议8次，出席股东大会会议5次，不存在连续两次未亲自出席会议的情况。任职期 间，本人按时亲自出席，没有委托出席或缺席情况。具体参会情况如下表： | 本年度应参加董 | 参加董事会 | 委托出席次 | 缺席次数 | 出席股东大会 | | --- | --- | --- | --- | --- | | 事会次数 | 次数 | 数 | | 次数 | | 8 | 8 | 0 | 0 | 5 | 武汉华康世纪医疗股份有限公司 独立董事述职报告 各位股东及股东代理人： 本人作为武汉华康世纪医疗股份有限公司(以下简称"公司")的独立董事、 第二届董事会提名委员会召集人、第二届董事会审计 ...

Dividend and Shareholder Information - The company plans to distribute a cash dividend of 1 RMB per 10 shares (including tax) to all shareholders, based on a total share capital of 105,600,000 shares[3]. - The company has a total of 105,600,000 shares outstanding, which will be the basis for the dividend distribution[3]. - The company’s financial report has been confirmed as true, accurate, and complete by its board of directors and management[3]. - The company maintains a consistent communication channel with investors through its official email and contact numbers[18]. Financial Performance - The company's operating revenue for 2023 reached ¥1,601,565,426.90, representing a year-on-year increase of 34.71% compared to ¥1,188,902,491.96 in 2022[21]. - The net profit attributable to shareholders of the listed company was ¥107,330,339.88, an increase of 4.72% from ¥102,488,728.44 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥90,844,431.31, showing a slight increase of 1.39% from ¥89,601,775.55 in 2022[21]. - The net cash flow from operating activities for 2023 was ¥187,360,309.21, a significant increase of 45.23% compared to ¥129,097,947.29 in 2022[21]. - The total assets at the end of 2023 amounted to ¥2,890,469,587.02, reflecting a year-on-year growth of 22.04% from ¥2,368,993,275.66 in 2022[21]. - The net assets attributable to shareholders of the listed company increased by 6.12% to ¥1,753,916,276.82 from ¥1,652,798,149.51 in 2022[21]. - The company reported a basic earnings per share of ¥1.02, up 3.03% from ¥0.99 in the previous year[21]. Government Support and Subsidies - The company received government subsidies amounting to ¥3,850,674.06, primarily related to awards for small and specialized enterprises[28]. - The total non-recurring gains and losses for 2023 amounted to ¥16,485,908.57, compared to ¥12,886,952.89 in 2022[28]. Research and Development - The R&D expenditure in 2023 was 3,327.8 billion yuan, a growth of 8.1% year-on-year, with basic research funding at 221.2 billion yuan, up 9.3%[40]. - The number of R&D personnel increased to 380 in 2023, representing a 72.73% increase from 220 in 2022[106]. - R&D investment amounted to ¥85,227,776.77 in 2023, up from ¥54,467,756.17 in 2022, reflecting a year-over-year increase of 56.49%[106]. - R&D expenditure as a percentage of operating revenue rose to 5.32% in 2023 from 4.58% in 2022[106]. Market and Industry Trends - In 2023, the number of medical and health institutions in China reached 1.071 million, an increase of 3.68% year-on-year, with hospitals totaling 39,000, up 5.41%[32]. - By the end of 2023, the elderly population aged 60 and above in China reached 297 million, accounting for 21.07% of the total population, an increase of 1.27% from the previous year[37]. - The healthcare budget for 2023 was set at 2,421.1 billion yuan, an increase of nearly 167 billion yuan compared to 2022[34]. - The laboratory construction industry is projected to reach 62.3 billion yuan by 2027, with a CAGR of 7.6% from 2022 to 2027[46]. Company Operations and Strategy - The company operates several wholly-owned subsidiaries, including Hebei Huakang and Hubei Feigete, enhancing its market presence[13]. - The company has actively expanded its laboratory business by forming dedicated teams and enhancing its service capabilities in planning, design, and operation[55]. - The company aims to leverage emerging technologies such as IoT and cloud computing to develop comprehensive solutions for smart medical information systems[49]. - The company is focusing on technological innovation and sustainable development despite facing challenges and cost pressures[101]. - The company is committed to enhancing its brand image and market position through advanced technology and improved service quality[101]. Investment and Fundraising - The total amount raised from the public offering was RMB 103,752 million, with a net amount of RMB 94,950.28 million after deducting issuance costs of RMB 8,801.72 million[129]. - As of December 31, 2023, the cumulative use of raised funds amounted to RMB 82,742.33 million, leaving a balance of RMB 14,224.29 million[130]. - The company has not made any securities or derivative investments during the reporting period[125][126]. - The company has approved changes to the investment project implementation主体, project用途, and total investment scale without altering the overall investment strategy[133]. Corporate Governance - The company has a clear governance structure, with independent operations of the board of directors and supervisory board[169]. - The company actively engages in investor relations, providing timely and accurate information to protect the interests of shareholders, especially minority shareholders[173]. - The company has a strategic committee, audit committee, nomination committee, and compensation committee to enhance decision-making efficiency[170]. - The company has implemented a robust internal control system to manage risks and ensure compliance with relevant regulations[175]. Management and Leadership - The company has maintained a stable management team with no significant changes in senior management roles during the reporting period[187]. - The company’s management team has a diverse professional background, contributing to its strategic direction and operational efficiency[189]. - The total remuneration for the board of directors, supervisors, and senior management in 2023 amounted to 5.3209 million yuan[199]. - The company has a compensation system based on profit-sharing for its directors, supervisors, and senior management[199].

Financial Performance - The company's revenue for Q1 2024 was ¥229,705,391.58, a decrease of 4.37% compared to ¥240,206,327.57 in the same period last year[5] - The net profit attributable to shareholders decreased by 85.28% to -¥32,071,670.93 from -¥17,309,522.74 year-on-year[5] - The net profit after deducting non-recurring gains and losses fell by 48.16% to -¥33,396,511.35 compared to -¥22,541,585.51 in the previous year[5] - Basic and diluted earnings per share decreased by 87.50% to -¥0.3 from -¥0.16 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 229,705,391.58, a decrease of 4.2% from CNY 240,206,327.57 in the same period last year[20] - Net loss for Q1 2024 was CNY 32,071,670.93, worsening from a net loss of CNY 17,309,522.74 in Q1 2023[22] - Basic and diluted earnings per share for Q1 2024 were both CNY -0.3, compared to CNY -0.16 in the previous year[22] Cash Flow and Assets - The operating cash flow net amount improved by 27.07%, reaching -¥150,043,637.68, compared to -¥205,749,592.42 in the same period last year[5] - The net cash flow from operating activities for Q1 2024 was -150,043,637.68 CNY, compared to -205,749,592.42 CNY in Q1 2023, showing an improvement of approximately 27%[25] - Total cash inflow from operating activities was 289,291,817.13 CNY, while cash outflow was 439,335,454.81 CNY, resulting in a net cash outflow of 150,043,637.68 CNY[25] - The ending cash and cash equivalents balance for Q1 2024 was 126,526,729.46 CNY, down from 429,125,286.77 CNY in Q1 2023, indicating a decrease of about 70%[26] - Cash and cash equivalents decreased from CNY 267,939,052.33 to CNY 206,540,180.12, a reduction of about 22.9%[18] - Total current assets decreased to CNY 2,009,578,720.32 from CNY 2,114,224,400.12, a decline of approximately 4.9%[18] - Total assets at the end of the reporting period were ¥2,801,209,875.26, a decrease of 3.09% from ¥2,890,469,587.02 at the end of the previous year[5] - Total assets decreased from CNY 2,890,469,587.02 to CNY 2,801,209,875.26, a decline of about 3.1%[18] Liabilities and Equity - Total liabilities decreased to CNY 1,074,587,320.77 from CNY 1,136,553,310.20 year-over-year[20] - Total equity attributable to shareholders decreased to CNY 1,726,622,554.49 from CNY 1,753,916,276.82 in the previous year[20] Operational Changes and Costs - The increase in operating costs was attributed to significant personnel growth and the opening of a new office building, which improved brand image but raised operational expenses[8] - The company is implementing comprehensive budgeting, process reforms, and personnel qualification assessments to enhance efficiency and reduce costs[8] - Total operating costs increased slightly to CNY 267,765,573.69, compared to CNY 267,516,174.95 in Q1 2023[20] - Research and development expenses for Q1 2024 were CNY 16,462,194.83, down from CNY 23,300,468.90 in Q1 2023, indicating a 29.3% reduction[20] - Sales expenses increased to CNY 39,120,819.56 from CNY 33,931,560.78, reflecting a 15.5% rise year-over-year[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,309[10] - The company has a total of 55,676,500 restricted shares, with 1,056,000 shares released from restriction during the period[15] - The company’s major shareholder, Tan Pingtao, holds 46,708,990 shares, which remain restricted until July 28, 2025[15] - The company’s employee stock ownership platform, Wuhan Kanghui Investment Management Center, holds 4,815,360 restricted shares, also set to be released on July 28, 2025[15] Accounts Receivable and Inventory - Accounts receivable decreased from CNY 1,371,620,009.09 to CNY 1,311,674,699.46, a decrease of approximately 4.4%[18] - Inventory increased from CNY 274,909,613.70 to CNY 286,941,781.54, an increase of about 4.4%[18] Borrowings and Financing Activities - Short-term borrowings increased from CNY 409,545,194.19 to CNY 562,037,777.78, an increase of approximately 37.2%[18] - The company received 270,000,000.00 CNY from borrowings in Q1 2024, compared to 100,000,000.00 CNY in Q1 2023, indicating a 170% increase in cash inflow from financing activities[26] - The net cash flow from financing activities was 165,475,678.21 CNY, up from 97,149,635.24 CNY in the same period last year, reflecting a growth of approximately 70%[26]

华英证券有限责任公司 关于武汉华康世纪医疗股份有限公司及其子公司 向银行申请综合授信额度及接受关联方担保 暨关联交易的核查意见 融资担保方式包括但不限于：公司控股股东及实际控制人谭平涛先生、胡小艳 女士的担保、公司固定资产抵押担保、公司应收账款质押担保等。 上述担保事项的具体担保期限以与相关银行签订的担保协议为准。 上述授信额度的申请期限为自2023年年度股东大会审议通过之日起1年。授信期 限内，授信额度可循环使用，各银行实际授信额度可在总额度范围内相互调剂。 上述授信额度内的单笔融资不再上报董事会或股东大会审议。公司董事会提请 股东大会授权公司董事长或其授权人代表公司签署上述授信额度内与授信相关的合 同、协议、凭证等各项法律文件，并可根据费用成本及各银行资信状况具体选择银 1 / 5 华英证券有限责任公司（以下简称"华英证券"或"保荐机构"）作为武汉华康世纪 医疗股份有限公司（以下简称"华康医疗"或"公司"）首次公开发行股票并在创业板上 市之保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所上市 公司自律监管指引第13号——保荐业务》、《深圳证券交易所创业板股票上市规则》、 《深圳证券交易所上 ...